Inhibition of Cdk2 kinase activity selectively targets the CD44+/CD24−/Low stem-like subpopulation and restores chemosensitivity of SUM149PT triple-negative breast cancer cellsMateusz Opyrchal, Antonino B. D’Assoro|International Journal of Oncology|2014Cited by 52
A Phase I Study of the Oral Dual-Acting Pan-PI3K/mTOR Inhibitor Bimiralisib in Patients with Advanced Solid TumorsFilip Jankú, Alex A. Adjei, Cinta Hierro et al.|Cancers|2024Cited by 13
Abstract B109: Oral dual PI3K/mTOR inhibitor bimiralisib demonstrates tolerability and a signal of activity in head and neck squamous cell cancer with NOTCH1 loss-of-function mutationFilip Jankú, Alex A. Adjei, Faye M. Johnson et al.|Molecular Cancer Therapeutics|2019Cited by 7